The purpose of the study is to see how mepolizumab affects the nasal microbiome, which is the community of bacteria and other microorganisms living in the nose, and the immune response in people with eGPA. Participants in the study will receive mepolizumab treatment, and researchers will observe changes in the nasal microbiome and immune response over time. The study will last for a period of 36 months, with regular check-ups to monitor the effects of the treatment.

By participating in this study, researchers hope to better understand how mepolizumab can help restore a healthy balance of microorganisms in the nose and improve the immune response in patients with eGPA. This could lead to better treatment options for managing the disease in the future.

The purpose of the study is to see how well Tezepelumab helps patients with EGPA maintain remission, which means the disease is not active, over a period of 24 weeks. Participants in the study will receive either Tezepelumab or a placebo through subcutaneous injection, which means the injection is given under the skin. The study is designed to be randomised and double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored to assess their response to the treatment. The main goal is to determine the proportion of patients who achieve remission by the end of the study period. Additionally, the study will look at the time it takes for any flare-ups of EGPA to occur and the total time participants remain in remission. This research aims to provide valuable insights into the potential benefits of Tezepelumab for individuals living with EGPA.

Participants in the study will receive either the Mepolizumab-based treatment or a conventional treatment, which may include medications like Cyclophosphamide and Azathioprine. Cyclophosphamide is a medication used to suppress the immune system, while Azathioprine is often used to prevent the body from rejecting transplanted organs and to treat autoimmune diseases. Some participants may also receive a placebo, which is a substance with no active medication, to help compare the effects of the treatments. The study will monitor the participants over a period to assess the impact of these treatments on their condition.

The main goal of the study is to determine if the Mepolizumab-based regimen can reduce the need for glucocorticoids, a type of steroid medication, in patients with newly diagnosed or relapsing EGPA. The study will track the dosage of a specific glucocorticoid called prednisone, aiming for a dose of 4.0 mg or less per day by a certain point in the study. Participants will be closely monitored for any changes in their condition, including any relapses or flare-ups of symptoms, as well as any side effects from the treatments. The study will provide valuable information on the potential benefits of Mepolizumab for managing EGPA.

The purpose of the study is to evaluate how effective and safe NS-229 is for treating people with EGPA. Participants in the study will be randomly assigned to receive either the NS-229 tablets or the placebo tablets. The study will last for a period of 28 weeks, during which time the health of the participants will be closely monitored. Researchers will be looking at how many participants experience remission, which means a reduction or disappearance of the symptoms of EGPA, and will also track any side effects or adverse events that occur.

Throughout the study, participants will have regular check-ups to assess their condition and to ensure their safety. The study aims to provide valuable information on whether NS-229 can be a beneficial treatment option for people with Eosinophilic Granulomatosis with Polyangiitis, potentially improving their quality of life by managing the symptoms of this challenging condition.

The purpose of the study is to evaluate how well these treatments work in helping patients achieve remission, which means the symptoms of EGPA are reduced or disappear. Participants in the study will receive either Benralizumab, Mepolizumab, or a placebo, along with their usual care. The study will last for about 52 weeks, with an additional open-label extension period where all participants may receive Benralizumab. During the study, participants will have regular check-ups to monitor their health and the effects of the treatment.

In addition to Benralizumab and Mepolizumab, the study involves other medications such as Prednisolone, Prednisone, and Methylprednisolone, which are types of glucocorticoids, a class of drugs that help reduce inflammation. The study aims to see how these treatments can help manage EGPA symptoms and improve the quality of life for patients. Participants will be closely monitored for any side effects or changes in their condition throughout the trial.

The purpose of the study is to evaluate how well Depemokimab works compared to Mepolizumab in adults with relapsing or refractory EGPA who are already receiving standard care. Participants will be randomly assigned to receive either Depemokimab, Mepolizumab, or a placebo. The study will last for 52 weeks, during which participants will receive regular injections and attend scheduled visits to monitor their health and the effects of the treatment.

Throughout the study, participants will be closely monitored to assess the duration of remission, which means a period when the disease is not active, and to track any relapses, which are episodes when the disease symptoms return. The study will also measure the amount of oral corticosteroids, a type of medication often used to manage EGPA, that participants need during the trial. This research will help determine if Depemokimab is as effective as Mepolizumab in managing EGPA symptoms and maintaining remission.